|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
1997-10-30
|
|
pubmed:abstractText |
To determine the maximum-tolerated dose (MTD) of cyclophosphamide (CTX) when administered over 2 consecutive days followed by hematopoetic stem-cell rescue given as two sequential courses to children with glioblastoma multiforme, poor-prognosis pontine gliomas, and other recurrent CNS tumors.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3258-65
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9336363-Adolescent,
pubmed-meshheading:9336363-Antineoplastic Agents, Alkylating,
pubmed-meshheading:9336363-Brain Neoplasms,
pubmed-meshheading:9336363-Child,
pubmed-meshheading:9336363-Child, Preschool,
pubmed-meshheading:9336363-Combined Modality Therapy,
pubmed-meshheading:9336363-Cyclophosphamide,
pubmed-meshheading:9336363-Female,
pubmed-meshheading:9336363-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:9336363-Humans,
pubmed-meshheading:9336363-Infant,
pubmed-meshheading:9336363-Male,
pubmed-meshheading:9336363-Neoplasm Recurrence, Local,
pubmed-meshheading:9336363-Prognosis,
pubmed-meshheading:9336363-Survival Rate
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
High-dose cyclophosphamide for poor-prognosis and recurrent pediatric brain tumors: a dose-escalation study.
|
|
pubmed:affiliation |
The Royal Hospital for Sick Children, Glasgow, United Kingdom.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
